Unit 4 week 2 Flashcards
Presentation of adrenal insufficiency (BOTH primary and secondary adrenal insufficiency)
1) Hyponatremia
2) Hypotension
3) Hypovolemia
4) Tachycardia
5) Hypoglycemia
6) Eosinophilia
+ fatigue, weakness, postural dizziness, anorexia, nausea, vomiting, diarrhea, abdominal pain, weight loss, myalgias, arthralgias, headache
Presentation of adrenal insufficiency ONLY present with primary AI
1) Hyperkalemia
2) Hyperpigmentation
3) Salt craving
Adrenal Crisis
symptoms (6) and treatment
EMERGENCY
-nausea, vomiting, fever, syncope, hypotension, tachycardia
GIVE STRESS DOSE STEROIDS (Hydrocortisone 100 mg IV every 8 hrs)
Tests for diagnosis of adrenal insufficiency (4)
1) Cortisol level (7-8am cortisol not > 16-18 → check ACTH with cortrosyn)
2) Cortrosyn (synthetic ACTH): stimulation test of adrenal reserve
- Baseline serum cortisol + IV injection of ACTH → serum cortisol at 30 and 60 minutes
3) Adrenal CT scan
4) Serum ACTH level
Primary vs. Secondary Adrenal Insufficiency
Primary = adrenal gland is not producing cortisol
Secondary = any cause upstream of adrenals
- ACTH NOT being produced
- adrenals are normal and respond normally to AGII –> normal aldo levels
Causes of Primary adrenal insufficiency
1) Addison’s Disease (autoimmune destruction)
2) Infectious - TB (most common cause in developing countries), Fungi, HIV
3) Amyloid infiltration of adrenals
4) Hemorrhagic, Metastatic, Surgical destruction of adrenals
Presentation of Primary adrenal insufficiency (4)
1) Hyponatremia
2) Hyperkalemia
3) Hypotension
4) Hyperpigmentation
Why do patients with primary AI have hyperkalemia? Why do they have hyperpigmentation?
Hyperkalemia due to lack cortisol AND ALDOSTERONE → hyponatremia, hyperkalemia
Hyperpigmentation due to Increased POMC (large ACTH precursor molecule)
–> increased ACTH and MSH (melanocyte stimulating hormone)
Diagnosis of Primary AI
4 tests and their findings
1) *Serum cortisol < 5ug/dL at baseline
2) *Plasma ACTH > 100 pg/ml
3) *Serum cortisol < 20ug/dl after Cosyntropin (ACTH stim test)
4) Adrenal CT Scan:
Small glands → autoimmune, metabolic
Large glands → all other causes
Treatment of primary adrenal insufficiency
glucocorticoids and mineralocorticoid replacement
- Hydrocortisone or prednisone (GC)
- Fludrocortisone (MC)
Causes of secondary adrenal insufficiency (3)
1) Supraphysiological exogenous glucocorticoids for > 3 weeks
2) Opioids
3) Hypothalamic/pituitary lesions (tumor, surgery, radiation, infection, hemorrhage, infiltrative, metastatic)
Presentation of secondary adrenal insufficiency
1) Hyponatremia
2) Hypotension, hypovolemia
3) NORMOkalemic (preserved aldo synthesis)
4) Low ACTH
5) No hyperpigmentation
Diagnosis of secondary adrenal insufficiency (4)
tests + results
1) Serum cortisol < 5ug/dl baseline
2) Serum cortisol < 20ug/dl after Cosyntropin (chronic secondary AI - may have normal ACTH response if this is new onset of AI and adrenals haven’t atrophied)
3) Plasma ACTH low or normal
4) MRI pituitary may show pathology
Treatment of secondary adrenal insufficiency
replace GCs only
No MC replacement required
Adrenal medullary catecholamines synthesis
what is rate limiting step?
what step does cortisol effect?
Tyrosine → DOPA (via tyrosine hydroxylase = RATE LIMITING STEP)
DOPA → DA → NE
NE → epinephrine (via PNMT = UPREGULATED BY CORTISOL)
Pheochromocytoma
Tumor of dark chromaffin cells → excess NE and epinephrine
Paraganglioma
pheochromocytoma outside the adrenal medulla
Genetics of pheochromocytoma
commonly associated with genetic abnormalities and familial syndromes
MEN (2A, 2B) - Ret gene mutation
VHL
NF-1
SDHB
SDHD
SDHB vs. SDHD genes in pheochromocytoma
SDHB = gene that significantly increases risk for malignant pheochromocytoma
- Dopamine secreting tumor associated with malignancy
- B FOR BAD
SDHD = AD, paternal inheritance
D FOR DAD
RET gene and pheochromocytoma
mutated in MEN2A, 2B
RET cell surface receptor somatic mutation → constitutive activation
Glial-derived neurotrophic growth factor (GDNF) binds RET → intracellular signaling stimulating cell synthesis of NE and EPI
Constellation of findings in: MEN2A (3)
Pheochromocytoma
Medullary thyroid carcinoma (Calcitonin-secreting C cells)
Hyperparathyroidism
Constellation of findings in: MEN2B (3)
Pheochromocycoma
Medullary thyroid carcinoma
Mucosal neuromas
Constellation of findings in: VHL (6)
pheochromocytoma RCC renal/pancreatic cysts CNS hemangioblastomas islet cell tumors retinal angiomas
Constellation of findings in: NF-1 (5)
pheochromocytoma hyperparathyroidism duodenal carcinoids medullary thyroid carcinoma optic nerve tumors
Clinical manifestations of pheochromocytoma
triad of symptoms + 3 other findings
TRIAD = headache, palpitations, diaphoresis
Hypertension (a1 vasoconstriction)
-Severely resistant to treatment
Increased HR, sweating and tremulousness (B1 receptors increase inotropic and chronotropic heart effects)
Vasodilation in muscle beds (B2 receptors)
Diagnosis of pheochromocytoma (3 tests)
1) 24 hour urinary collection
2) CT/MRI to localize tumor
3) I-123 MIBG scan: localization for extra-adrenal, recurrent, and metastatic tumors
24 hour urine collection in pheochromocytoma
- Catecholamines (Epi, NE) –> Not as reliable, needle stick can cause a rush of catecholamines
- Metabolites (metanephrines, normetanephrines, VMA) (can do serum also)
Medications that can interfere with 24 hr urine levels of catecholamines and metabolites (4)
Interfering medications: can falsely elevate catecholamines / metabolites
Acetaminophen
SSRIs, SNRIs
Marijuana and other illicit drugs
Treatment of pheochromocytoma
1) Surgical removal
2) Alpha-adrenergic blocker (phenoxybenzamine)
3) B-blocker (labetalol)
DO NOT start B-blocker before a-blocker
4) Ca2+ channel blocker
Licorice ingestion and hyperaldosteronism?
(pseudohypoaldosteronism): licorice prevents inactivation of cortisol in kidney
→ HTN and hypokalemia
Causes of secondary aldosteronism (2)
Cirrhosis
Heart failure
Primary aldosteronism (Conn’s Syndrome)
Adrenal cortex (glomerulosa) primarily secretes too much aldosterone
- Low renin and angiotensin II (under normal feedback mechanisms)
- RAAS feedback loop is perturbed
Most common cause of secondary hypertension
Primary aldosteronism (Conn’s Syndrome)
Presentation (6)
1) Resistant hypertension
- HTN at a young age, HTN resistant to multiple anti HTN meds, stage 2 HTN (>160/100)
2) Hypokalemia - may be very severe or normal
3) Metabolic alkalosis
4) Muscle weakness
5) Mild hypernatremia
6) Presence of adrenal adenoma possible
Primary aldosteronism (Conn’s Syndrome)
Diagnosis (4)
1) Aldosterone:Renin Ratio: ratio > 20
- High plasma aldosterone, low plasma renin
2) IV saline suppression test
-IV saline should suppress aldosterone, but if they have primary aldosteronism → no aldo suppression
Aldo > 10 ng/dL confirms dx
3) CT or MRI to look for adenoma or hyperplasia
4) Adrenal Vein Sampling (AVS) for lateralization (look for difference in aldosterone levels between R and L adrenal vein)
Which medications should be stopped before getting plasma renin and aldosterone levels?
Must STOP interfering medications before testing (spironolactone, eplerenone)
Treatment of primary aldosteronism
Surgical cure
Bilateral adrenal hyperplasia or non-surgical candidate → treat with mineralocorticoid antagonist (spironolactone or eplerenone)
4 types of primary aldosteronism
1) Aldosterone producing adenoma (34%)
2) Idiopathic hyperaldosteronism (bilateral adrenal hyperplasia) (66%)
3) Glucocorticoid remediable hyperaldosteronism
4) Aldosterone-producing carcinoma
Glucocorticoid remediable hyperaldosteronism
mechanism?
genetic rearrangement fusing regulatory promoter of 11-B hydroxylase with structural component of aldosterone synthase → aldosterone synthase under positive control of ACTH
–> increased aldosterone synthesis in response to ACTH
3 main categories of Cushing’s Syndrome
1) Iatrogenic (chronic administration of GCs - most common)
2) ACTH dependent
3) ACTH independent: high cortisol production, low ACTH, feedback mechanism still works
Causes of ACTH dependent Cushing’s Syndrome
1) Pituitary adenoma (Cushing’s Disease)
2) Ectopic ACTH Syndrome (small cell lung cancer)
Pituitary adenoma (Cushing’s Disease)
ACTH and cortisol levels
High ACTH, high cortisol
Feedback mechanism does not turn off ACTH
Ectopic ACTH Syndrome
ACTH and cortisol levels
VERY high ACTH, VERY high cortisol
Feedback mechanism does not turn off ACTH
Causes of ACTH independent Cushing’s Syndrome
Adrenal Adenoma
Adrenal Carcinoma
Nodular Adrenal Hyperplasia
high cortisol production, low ACTH, feedback mechanism still works
3 steps for working up Cushing’s syndrome
1) Establish patient has Cushing’s syndrome
2) Determine etiology of hypercortisolism ACTH level (ACTH dependent vs. independent)
3) 3) Determine if ACTH is ectopic or from pituitary
Tests that can establish if a patient has Cushing’s syndrome (3)
1) 24 hr urinary free cortisol
2) 1 mg dexamethasone suppression test (cortisol should be low after dexamethasone)
3) Midnight salivary cortisol elevated (cortisol should be LOWEST at midnight)
What test can distinguish between ACTH dependent vs. independent Cushing’s Sydrome
ACTH level
How can you determine if ACTH production is ectopic or from pituitary? (3 tests)
1) CT, MRI, ultrasonography, isotope scanning
2) 8 mg dex suppression test
3) Inferior petrosal sinus sampling
8 mg dex suppression test - for what? tells you what?
determine if ACTH production is ectopic or from pituitary
Pituitary source: cortisol suppresses to < 5 ng/dL because still some sensitivity of pituitary corticotroph cells
Not very reliable
Inferior petrosal sinus sampling
measure baseline ACTH at intervals after stimulation with CRH
Pit source → ACTH should be higher in petrosal sinus than central IVC
Ectopic source → ACTH similar in sinus and central IVC
Adrenal incidentalomas
adrenal gland tumors are common, most clinically insignificant, majority are non-functioning
Initial evaluation of Adrenal incidentalomas must exclude:
1) Benign or Malignant? Radiographic appearance
2) Functional or nonfunctional?
Determining benign or malignant nature of adrenal incidentaloma
Malignant: size? shape? lipid density? signal intensity?
Benign: < \_\_\_\_\_\_\_ size \_\_\_\_\_\_\_ with \_\_\_\_\_\_\_\_ borders HU is \_\_\_\_\_\_ on noncontrast CT \_\_\_\_\_\_\_ lipid content \_\_\_\_\_\_\_\_\_\_ occurs on out of phase imaging
Malignant: Large, irregular, lipid-poor lesion with higher signal intensity (high HU, > 10)
Benign:
-< 4 cm in size
-Homogenous with smooth/regular borders
-HU < 10 on non-contrast CT
-High intracellular lipid content, density closer to water and fat
-Signal dropout on out of phase imaging
Rapid enhancement of contrast, rapid loss of contrast (>50% washout)
MRI is as effective as CT scanning for distinguishing benign from malignant lesions
Adrenal incidentalomas
Functional or nonfunctional?
what tests should you order to determine this? (3)
1) Plasma metanephrines or 24 hr urine mets/cats
SCREEN FOR PHEOCHROMOCYTOMA
2) 1 mg overnight dex suppression test
SCREEN FOR HYPERCORTISOLISM
3) If patient is hypertensive, screen for primary aldosteronism with aldosterone/plasma renin level
Adrenocorticosteroids:
____________ effects can NOT be separated from anti-inflammatory effects and ___________ effects cannot be separated from immunosuppressive effects
Metabolic effects can NOT be separated from anti-inflammatory effects and anti-inflammatory effects can NOT be separated from immunosuppressive effects
Hydrocortisone
MC:GC Activity
Route of administration
Clinical Use
MC:GC Activity: 1:1
Route of administration: TOPICAL, oral, injectable
Clinical Use:
- Used in PHYSIOLOGIC replacement regimens
- Must be given several times daily
Prednisone
MC:GC Activity
Route of administration
Clinical Use
MC:GC Activity: 1:5
Route of administration: oral (NOT TOPICAL)
Clinical Use: most commonly used oral agent for steroid burst therapy
Dosing considerations with prednisone?
MUST be activated to prednisolone in liver**
Cannot be given topically
Dexamethasone
MC:GC Activity
Route of administration
Clinical Use
Adverse effects
MC:GC Activity: 0:30 → all GCC activity
Route of administration: oral, injectable, TOPICAL
Clinical Use: used for anti-inflammatory/immunosuppressive actions
- Most potent anti-inflammatory agent
- Used in cerebral edema, chemo-induced vomiting
- Big suppression of ACTH secretion from pituitary
Adverse effects: Significant metabolic side effects
Triamcinolone
potent systemic agent with excellent topical activity
NO MC action
Fludrocortisone
MC:GC Activity: 125-200:10 → Primarily MC activity without GC / anti-inflammatory activity
High doses can cause hypokalemia
Treatment of Addison’s Disease
reat with physiologic replacement therapy (MC and GC replacement required)
Cortisol (GC replacement) + Fludrocortisone (MC replacement) + DHEA (sex steroid replacement for women)
3 main categories of drugs that can be used to treat Cushing’s Syndrome
1) ACTH secretion inhibitors
2) Cortisol synthesis inhibitors
3) Cortisol Receptor Antagonist
ACTH secretion inhibitors (2)
Cabergoline (D2 agonist)
Pasireotide (SST analog)
Ketoconazole
Cortisol synthesis inhibitor
inhibits CYP450 androgen synthesis in testes and inhibits cholesterol → pregnenolone, reduces cortisol synthesis
Adverse effects: headache, N/V, gynecomastia, impotence, reversible hepatotoxicity
Mifepristone
Cortisol Receptor Antagonist
-anti-progestational drug that blocks GC receptors at higher doses
Not first line
Used to control hyperglycemia secondary to hypercortisolism
Contraindicated in pregnancy
Treatment of Primary aldosteronism
goal is to normalized hypokalemia and BP before surgical removal of tumor
Aldo antagonists: Spironolactone, eplerenone
BP meds: Ca2+ channel blockers, ACEI, ARB
Metyrosine
competitive inhibitor of catecholamine synthesis
used to treat pheochromocytoma that is non-surgical
Thyronine
backbone of THs with 3, 5, 3’, and 5’ positions that can be iodinated
Thyroxine (T4) vs. T3
Thyroxine (T4) = 3, 5, 3’, 5’ tetraiodothyronine
T3 = 3, 5, 3’ triiodothyronine
Iodide trap
Membrane pump on basal side of follicular cell promotes accumulation of iodide in thyroid 30-40x concentration in serum
4 steps of iodine uptake by thyroid gland
1) Na+/I- symporter + Na/K ATPase on basal side brings I- into cell
2) Iodide diffuses from basal (blood) → apical (lumen) side of follicular cell
3) Iodide oxidized (I- → I2) by thyroid peroxidase
4) Organification of I2 (incorporation of iodide into tyrosyl residues on thyroglobulin) occurs at follicular cell-colloid interface
Thyroperoxidase
membrane bound glycoprotein/enzyme in thyroid that catalyzed iodination of thyroglobulin, organification of I2, and coupling of DITs/MITs
Synthesis and Release of Thyroglobulin
Thyroglobulin synthesized in RER of follicular cell and transported to Golgi apparatus to be glycosylated and packaged into secretory vesicles
Secretory vesicles released from apical follicular cell into lumen (colloid)
Undergoes iodination and coupling reactions to synthesize TH at tyrosyl residues
Steps of Thyroid Hormone Synthesis
thyroperoxidase catalyzes iodination of tyrosyl moieties on TG → mono/di- iodotyrosine (MIT/DIT) formed on TG
Thyroperoxidase also catalyzes coupling of 2 DITs or 1 DIT and 1 MIT to form iodothyronines
Steps of thyroid hormone release
Drops of colloid endocytosed into follicular cells → coalesce with lysosomes → lysosomal enzymes act on TG to cleave T4 and T3 from TG
10-20x more T4 removed than T3
Thyroid Hormone Transport
Most thyroid hormone in a protein bound form
Some exist in free form (0.03% of T4, and 0.4% of T3)
thyroid hormone in a protein bound form
binds with what 3 proteins?
what is the effect of protein binding?
Thyroid binding proteins:
1) Thyroid binding globulin (TBG)
2) Thyroid binding pre-albumin (TBPA)
3) Albumin
Delay, buffer and prolong effects of TH action
half life of T4 vs. T3
T ½ for T4 is 7 days, and T3 is 1 day because TBG has a higher affinity for T4
Free thyroid hormone
Free form is active form
Must measure plasma TH values for bound or free form in addition to total TH in blood
How is T4 converted to T3?
T4 → T3 by 5’-deiodinase in the target cell
Cellular actions of thyroid hormone
- T3 has a higher affinity for TH receptor, so is more active than T4
- T3/T4 enter cell by ACTIVE TRANSPORT
T4 → T3 by 5’-deiodinase
T3 enters nucleus → interacts with nuclear receptors → T3-receptor complex acts on DNA to direct transcription of specific mRNAs
5 main actions of thyroid hormone
1) Metabolic rate
2) Fetal and neonatal brain development
3) TH and GH necessary for normal growth
4) Enhance response to catecholamines
5) Metabolic effects
How does thyroid hormone effect metabolic rate?
THs increase basal metabolic rate and increase oxygen consumption = Calorigenic effect
Mostly due to Na/K pump upregulation
Thyroid hormone and catecholamines
TH enhances response to catecholamines: TH mimics effects of SNS by increasing number of B-adrenergic receptors = permissive effect
Thyroid hormone and metabolic effects
low/moderate dose of TH vs. high dose of TH
Low/Moderate doses of TH → anabolic
-Promote conversion of glucose → glycogen
High doses of TH → catabolic
-Increased fuel consumption, protein breakdown, muscle wasting, glycogenolysis, and lipolysis
TSH and its actions on the thyroid gland
TSH → thyroid gland where it interacts with membrane receptor, stimulating thyroid hormone synthesis via increases in cAMP
TSH stimulates:
1) Iodide pump
2) Thyroperoxidase
3) Endocytosis of colloid
4) Iodide organification
5) Coupling of iodotyrosines
6) TG synthesis and its proteolysis following endocytosis
7) Follicular cell proliferation, elongation, and enlargement
3 drugs that block thyroperoxidase and conversion of T4 to T3 in target cells
Thioureas, propylthiouracil, methimazole
Signs/Symptoms of Hyperthyroidism (10)
BMR Nervousness Pretibial myxedema (Graves) Heat intolerance Muscle weakness Goiter Palpitations Exophthalmos (Graves) Lid retraction (Graves) Tachycardia
In what cases would you have an elevated total T4/T3, but a normal free T4/T3?
Total T4/T3 can be elevated with increases in thyroid binding proteins (e.g. high estrogen states), but free T4/T3 will not be affected